Amplia Therapeutics (ASX:ATX) announced that its Phase 2a clinical trial, ACCENT, has achieved significant progress.
The trial, investigating narmafotinib in combination with standard chemotherapy for advanced pancreatic cancer, has documented tumour size reductions in six patients out of the 16 assessed at the four-month mark.
The milestone permits the recruitment of an additional 24 patients, bringing the total number of trial participants to 50.
Recruitment is set to commence immediately at existing trial sites in Australia and South Korea, with completion expected by the end of the first quarter of 2025.
Amplia CEO and Managing Director Dr Chris Burns stated, “Having now confirmed our sixth PR, we will move forward with recruiting the remaining 24 patients for the trial. We are actively working with our clinical sites to ensure seamless reopening of enrolment with the goal of completing recruitment by the end of March 2025."
The ACCENT trial has shown that narmafotinib is generally well tolerated with no safety trends or dose reductions noted so far.
Alongside six partial responses, seven patients have recorded stable disease for over two months, with one later achieving a partial response.
Detailed interim analysis of the trial data will be released in the coming weeks, offering further insights into the drug's efficacy and safety profile.
At the time of reporting, Amplia Therapeutics' share price was $0.15.